Singapore markets open in 4 hours 52 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
231.93-1.88 (-0.80%)
As of 03:08PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close233.81
Open235.51
Bid231.14 x 800
Ask231.36 x 900
Day's range230.90 - 235.51
52-week range217.10 - 468.55
Volume674,720
Avg. volume1,574,406
Market cap34.069B
Beta (5Y monthly)0.42
PE ratio (TTM)22.70
EPS (TTM)10.22
Earnings date01 Feb 2022 - 07 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est290.37
  • Zacks

    Ionis' (IONS) Partner to Begin New Huntington's Disease Study

    Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.

  • Motley Fool

    Is Biogen a Buy After the Latest Aduhelm Disaster?

    Biogen's (NASDAQ: BIIB) stock is taking yet another body blow since the Centers for Medicare and Medicaid Services (CMS) issued a draft ruling on Jan. 12 that the company's troubled new Alzheimer's drug, Aduhelm, wouldn't be covered by the U.S. public insurance plans except in the context of patients enrolled in clinical trials. In my view, there isn't much hope for Aduhelm's fortunes to reverse anytime soon.

  • Motley Fool

    Where Will Biogen Be in 5 Years?

    Biogen (NASDAQ: BIIB) investors recently received an unwelcome surprise from an important government agency. The phrase "coverage with evidence development" (CED) might not sound too serious, but these words from the Centers for Medicare & Medicaid Services (CMS) were heavy enough to put Biogen's stock price under pressure on Wednesday, Jan. 12, 2022. The CMS decision was tough on Biogen stock price in the short term, but what do the next five years have in store?